Landscape of long-acting formulations and delivery platforms for HIV prevention and treatment

The first session in the series Accelerating access to long-acting HIV prevention and treatment formulations and delivery platforms: Challenges and opportunities will frame and present an overview of long-acting formulations and delivery platforms for HIV prevention and treatment currently available and in the pipeline. Industry representatives will outline the current opportunities and challenges, as well the population and context for each type of formulation and delivery platforms. Invited attendees will have the opportunity to share their perspectives during a moderated open-floor discussion. 

The aim of the session is to: 1) present up-to-date information on the currently available and upcoming prevention and treatment formulations and delivery platforms; 2) outline their opportunities and challenges; and 3) hear perspectives from communities, civil society, ministries of health and healthcare providers on what is available and in the pipeline.  

View session 2 of the series here and session 3 here

5 May 2022
Chairs

Anton Pozniak

Consultant Physician in HIV Medicine

Chelsea and Westminster Hospital and Professor, UK

Helen McDowell

Head of Government Affairs & Global Public Health

ViiV Healthcare

Speakers

Michelle Rodolph

Technical Officer

World Health Organization, Switzerland

Upcoming guidelines of long-acting formulations and delivery methods for HIV prevention

Brent Allan

Global community engagement consultant

Australia

Rahab Mwaniki

Civil society leader and public health specialist

Kenya

Moses "Supercharger" Nsubuga

Musician, radio and TV presenter and HIV advocate

Uganda

Kenly Sikwese

AFROCAB, Zambia

Rapid fire perspectives from community and civil society on the long-acting formulations and delivery platforms

Charles Flexner

Johns Hopkins University, USA

What’s in the pipeline: Long-acting drugs for treatment and prevention

Alex Rinehart

Medicines Development Leader, Prevention

ViiV Healthcare

Update on the long-acting formulations and delivery methods

Kathleen E. Squires

Global Director of Scientific Affairs

Merck Research Laboratories, USA

Update on the long-acting formulations and delivery methods

Martin Rhee

Executive Director in Clinical Research in Virology

Gilead Sciences

Update on the long-acting formulations and delivery methods

Gustavo Doncel

Scientific and Executive Director

Eastern Virginia Medical School, CONRAD, USA

Opening of panel discussion
Panelists

Michelle Rodolph

Technical Officer

World Health Organization, Switzerland

Brent Allan

Global community engagement consultant

Australia

Rahab Mwaniki

Civil society leader and public health specialist

Kenya

Moses "Supercharger" Nsubuga

Musician, radio and TV presenter and HIV advocate

Uganda

Kenly Sikwese

AFROCAB, Zambia

Charles Flexner

Johns Hopkins University, USA

Alex Rinehart

Medicines Development Leader, Prevention

ViiV Healthcare

Kathleen E. Squires

Global Director of Scientific Affairs

Merck Research Laboratories, USA

Martin Rhee

Executive Director in Clinical Research in Virology

Gilead Sciences

Gustavo Doncel

Scientific and Executive Director

Eastern Virginia Medical School, CONRAD, USA